[3P-0652] The development of drug screening system for dysferlinopathy using patient derived iPS cells

〇Yuko Kokubu^1,3, Tomoko Nagino^2,3, Katunori Sasa^2,3, Tatsuo Oikawa^2,3, Katsuya Miyake⁴, Mikiko Fukuda^1,3, Ryuichi Tozawa^2,3, Hidetoshi Sakurai^1,3 (1.Center for iPS Cell Research and Application (CiRA), Kyoto University, 2.Regenerative Medicine Unit, Takeda Pharmaceutical company Ltd., 3.Takeda-CiRA joint program (T-CiRA) , 4.International University of Health and Welfare)

iPS, drug screening, skeletal muscle